Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors
一项针对晚期实体瘤患者的Ib期研究，评估了CSF-1R抑制剂pexidartinib（PLX3397）与紫杉醇联合用药的疗效。
期刊:Therapeutic Advances in Medical Oncology
影响因子:4.2
doi:10.1177/1758835919854238
Wesolowski, Robert; Sharma, Neelesh; Reebel, Laura; Rodal, Mary Beth; Peck, Alexandra; West, Brian L; Marimuthu, Adhirai; Severson, Paul; Karlin, David A; Dowlati, Afshin; Le, Mai H; Coussens, Lisa M; Rugo, Hope S
